Impact of Pre-Admission Statin Use on Severity of Pandemic Influenza A(H1N1)
Author Information
Author(s): Brett Stephen J., Myles Puja, Lim Wei Shen, Enstone Joanne E., Bannister Barbara, Semple Malcolm G., Read Robert C., Taylor Bruce L., McMenamin Jim, Nicholson Karl G., Nguyen-Van-Tam Jonathan S., Openshaw Peter J. M.
Primary Institution: Imperial College Healthcare NHS Trust, London, United Kingdom
Hypothesis
Does pre-admission statin use affect the severity of illness in patients hospitalized with pandemic influenza A(H1N1)?
Conclusion
Pre-admission statin use did not show a significant beneficial effect on the severity of illness in hospitalized patients with pandemic influenza A(H1N1).
Supporting Evidence
- Statins are commonly used to lower cholesterol and may have effects on inflammation.
- The study analyzed data from 1,520 patients with confirmed influenza A(H1N1) infection.
- Only patients aged 35 and older were included in the analysis.
- Statin use was not associated with a statistically significant reduction in severe outcomes.
Takeaway
The study looked at whether taking cholesterol-lowering drugs called statins helps people who get really sick from a type of flu. It found that taking statins didn't seem to make a difference in how sick people got.
Methodology
A retrospective case-control study using data from the UK Influenza Clinical Information Network (FLU-CIN) database.
Potential Biases
Potential confounding by indication due to the health status of statin users.
Limitations
The study may have been underpowered to detect a modest benefit of statins, and it only included hospitalized patients.
Participant Demographics
Patients aged 35 years and older, with a mean age of 52 years, 44% male.
Statistical Information
Confidence Interval
0.38–1.33
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website